Cargando…
Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center
Background: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor with intermediate malignancy that tends to affect children primarily. To date, no standardized therapies exist for the treatment of IMT. This study aimed to share experience from China Children’s Medical Center for the...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947196/ https://www.ncbi.nlm.nih.gov/pubmed/35327685 http://dx.doi.org/10.3390/children9030307 |
_version_ | 1784674381542195200 |
---|---|
author | Dong, Youhong Zahid, Kashif Rafiq Han, Yidi Hu, Pengchao Zhang, Dongdong |
author_facet | Dong, Youhong Zahid, Kashif Rafiq Han, Yidi Hu, Pengchao Zhang, Dongdong |
author_sort | Dong, Youhong |
collection | PubMed |
description | Background: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor with intermediate malignancy that tends to affect children primarily. To date, no standardized therapies exist for the treatment of IMT. This study aimed to share experience from China Children’s Medical Center for the explorative treatment of IMT. Methods: Patients with newly diagnosed IMT between January 2013 and December 2018 were included. Patients were grouped according to surgical margins and Intergroup Rhabdomyosarcoma Study Group (IRSG) staging. The clinical characteristic, therapeutic schedules, treatment response and clinical outcome were described. Results: Six patients were enrolled in this study, including two boys and four girls, with a median age of 57 months (range 10–148 months). Among them, five patients were anaplastic lymphoma kinase positive. Four patients achieved complete remission and two patients attained partial remission after treatment with this protocol. All patients were alive after a median follow-up of 4 years (range 3–7 years). The most common treatment-related adverse reaction was myelosuppression. Conclusion: In this study, we demonstrated that IMT has a good prognosis and the treatment selected according to risk stratification was effective and feasible. |
format | Online Article Text |
id | pubmed-8947196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89471962022-03-25 Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center Dong, Youhong Zahid, Kashif Rafiq Han, Yidi Hu, Pengchao Zhang, Dongdong Children (Basel) Brief Report Background: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor with intermediate malignancy that tends to affect children primarily. To date, no standardized therapies exist for the treatment of IMT. This study aimed to share experience from China Children’s Medical Center for the explorative treatment of IMT. Methods: Patients with newly diagnosed IMT between January 2013 and December 2018 were included. Patients were grouped according to surgical margins and Intergroup Rhabdomyosarcoma Study Group (IRSG) staging. The clinical characteristic, therapeutic schedules, treatment response and clinical outcome were described. Results: Six patients were enrolled in this study, including two boys and four girls, with a median age of 57 months (range 10–148 months). Among them, five patients were anaplastic lymphoma kinase positive. Four patients achieved complete remission and two patients attained partial remission after treatment with this protocol. All patients were alive after a median follow-up of 4 years (range 3–7 years). The most common treatment-related adverse reaction was myelosuppression. Conclusion: In this study, we demonstrated that IMT has a good prognosis and the treatment selected according to risk stratification was effective and feasible. MDPI 2022-02-24 /pmc/articles/PMC8947196/ /pubmed/35327685 http://dx.doi.org/10.3390/children9030307 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Dong, Youhong Zahid, Kashif Rafiq Han, Yidi Hu, Pengchao Zhang, Dongdong Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center |
title | Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center |
title_full | Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center |
title_fullStr | Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center |
title_full_unstemmed | Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center |
title_short | Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center |
title_sort | treatment of pediatric inflammatory myofibroblastic tumor: the experience from china children’s medical center |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947196/ https://www.ncbi.nlm.nih.gov/pubmed/35327685 http://dx.doi.org/10.3390/children9030307 |
work_keys_str_mv | AT dongyouhong treatmentofpediatricinflammatorymyofibroblastictumortheexperiencefromchinachildrensmedicalcenter AT zahidkashifrafiq treatmentofpediatricinflammatorymyofibroblastictumortheexperiencefromchinachildrensmedicalcenter AT hanyidi treatmentofpediatricinflammatorymyofibroblastictumortheexperiencefromchinachildrensmedicalcenter AT hupengchao treatmentofpediatricinflammatorymyofibroblastictumortheexperiencefromchinachildrensmedicalcenter AT zhangdongdong treatmentofpediatricinflammatorymyofibroblastictumortheexperiencefromchinachildrensmedicalcenter |